Companies / BOC Sciences / Farletuzumab
BOC Sciences

Farletuzumab | BOC Sciences

Farletuzumab is a humanized monoclonal antibody that binds to GP-3 antigen and triggers a host immune response against GP-3 expressing cells. Farletuzumab has been investigated for the treatment of ovarian cancer.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.